Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with Philadelphia chromosome-positive chronic-phase CML after treatment with at least two tyrosine kinase inhibitors.
LAMPGEN ANALYSIS
Why it matters
The action confirms the original accelerated approval for previously treated chronic-phase disease.
What research teams should watch
Reconcile prior TKI exposure and distinguish this conversion from the separate T315I-mutated indication.
PRIMARY RECORDS